IPO~$67.8M net
Vogenx Prices $68M IPO for Metabolic Drug
Vogenx priced 6.25M shares at $12 to raise roughly $68M net, funding development of mizagliflozin, an SGLT1 inhibitor for gastrointestinal and metabolic disorders, through 2028.
Is something wrong on this page?
Recent changes
- Aug 5, 2026Aug 5, 2026Vogenx Prices $68M IPO for Metabolic Drug Pulse story
- Jul 15, 2026Jul 15, 2026Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue Pulse story
Latest Pulse
- Aug 5, 2026Vogenx Prices $68M IPO for Metabolic DrugVogenx priced 6.25M shares at $12 to raise roughly $68M net, funding development of mizagliflozin, an SGLT1 inhibitor for gastrointestinal and metabolic disorders, through 2028.→
- Jul 16, 2026The IPO Pipeline Is Quietly Getting LongerValue Add Pulse analysis: the mix of filings landing in mid-July 2026 -- SPAC revival, sustained biotech S-1s, mega-cap AI IPO prep and a wobbling SpaceX debut -- shows a pipeline broadening in kind, not just size.→
- Jul 15, 2026Jaguar Health, Vogenx Join a Growing Biotech S-1 QueueJaguar Health and Vogenx both filed S-1 paperwork with the SEC, adding to a biotech IPO queue that's grown steadily through 2026 as public-market appetite for clinical-stage listings recovers.→
Coverage Timeline
newest firstAll Coverage
Vogenx Prices $68M IPO for Metabolic Drug
Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue
IPO
Jaguar Health, Vogenx Join a Growing Biotech S-1 Queue
Jaguar Health and Vogenx both filed S-1 paperwork with the SEC, adding to a biotech IPO queue that's grown steadily through 2026 as public-market appetite for clinical-stage listings recovers.